AI Centres for Longevity Recommendation
TOTAL SCORE: 10
Score
A1 (Feasibility increased by continuance of pandemic): 0
A2 (Necessity increased by covid pandemic):
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): +1
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): +1
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): +1
D6 (Reorganisation): 0
E (Disruptiveness): +1
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
RECOMMENDATION SUMMARY
We propose that the Government support the establishment of the first AI Centre for Longevity. Optimal locations for this purpose would already have dedicated divisions and resources both for AI and for Longevity -- constellations of both AI and Longevity expertise, divisions and resources. And a physical location suitable for engaging in cross-sector and industry-academic collaboration.
We also recommend that the UK Government use the first such centre as a case study to quantitatively assess the feasibility and practicality of using it as an example for the later establishment of four leading AI Centres for Longevity across the UK in key metropolitan, industrial and academic R&D hubs (such as Liverpool, Birmingham and Edinburgh), in much the same way that the UK has supported the development of 4 Centres for AI in Healthcare.
Currently, there are only 3 centres in the world actively trying to establish a leading AI Centre for Longevity. These include the US-based Buck Institute for Research on Aging, US-based Y Combinator, and the US-Hawaii AI Precision Health Institute, while only the latter has actually succeeded in establishing such a centre in practice. If the UK were to work toward the establishment of such centres in a proactive manner, the nation could leverage its existing resources, including its very well-developed AI industry and its reputation for extremely strong industry-academic-governmental cooperative initiatives, to become the #1 global hub for AI
Centres for Longevity.
The Government should also take into consideration the possibility of using the existing Centres for AI in Healthcare as a basis and foundation for these three additional proposed AI Centres for Longevity, building upon their existing resources and accomplishments to more efficiently and economically develop these centres - but only in the event that such centres have existing assets and resources not only in AI, but also in the science of Longevity.
Score
A1 (Feasibility increased by continuance of pandemic): 0
A2 (Necessity increased by covid pandemic):
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): +1
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): +1
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): +1
D6 (Reorganisation): 0
E (Disruptiveness): +1
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
RECOMMENDATION SUMMARY
We propose that the Government support the establishment of the first AI Centre for Longevity. Optimal locations for this purpose would already have dedicated divisions and resources both for AI and for Longevity -- constellations of both AI and Longevity expertise, divisions and resources. And a physical location suitable for engaging in cross-sector and industry-academic collaboration.
We also recommend that the UK Government use the first such centre as a case study to quantitatively assess the feasibility and practicality of using it as an example for the later establishment of four leading AI Centres for Longevity across the UK in key metropolitan, industrial and academic R&D hubs (such as Liverpool, Birmingham and Edinburgh), in much the same way that the UK has supported the development of 4 Centres for AI in Healthcare.
Currently, there are only 3 centres in the world actively trying to establish a leading AI Centre for Longevity. These include the US-based Buck Institute for Research on Aging, US-based Y Combinator, and the US-Hawaii AI Precision Health Institute, while only the latter has actually succeeded in establishing such a centre in practice. If the UK were to work toward the establishment of such centres in a proactive manner, the nation could leverage its existing resources, including its very well-developed AI industry and its reputation for extremely strong industry-academic-governmental cooperative initiatives, to become the #1 global hub for AI
Centres for Longevity.
The Government should also take into consideration the possibility of using the existing Centres for AI in Healthcare as a basis and foundation for these three additional proposed AI Centres for Longevity, building upon their existing resources and accomplishments to more efficiently and economically develop these centres - but only in the event that such centres have existing assets and resources not only in AI, but also in the science of Longevity.